PARP inhibitors in ovarian cancer: current status and future promise (Q38194324)

30 August 2017

1 reference

title

PARP inhibitors in ovarian cancer: current status and future promise (English)

1 reference

30 August 2017

1 reference

3

Ursula A Matulonis

1 reference

30 August 2017

Joyce F Liu

1

1 reference

PubMed ID

24607283

30 August 2017

Panagiotis A Konstantinopoulos

series ordinal

2

1 reference

PubMed ID

24607283

30 August 2017

language of work or name

English

0 references

publication date

4 March 2014

1 reference

30 August 2017

1 reference

30 August 2017

133

1 reference

30 August 2017

2

1 reference

30 August 2017

362-369

1 reference

Molecular pathways: targeting PARP in cancer treatment

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

The DNA damage response and cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

PARP inhibition: PARP1 and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Hereditary ovarian cancer: beyond the usual suspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Appraising iniparib, the PARP inhibitor that never was--what must we learn?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Mechanisms of resistance to therapies targeting BRCA-mutant cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

"Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

The biology of ovarian cancer: new opportunities for translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.039

10.1016/J.YGYNO.2014.02.039

7 January 2021

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24607283